https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-present-at-the-h.c.-wainwright-bioconnect-virtual-conference
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-fda-approval-and-imminent-launch-of-rifabutin-capsules
https://www.nasdaq.com/press-release/eton-pharmaceuticals-and-ani-pharmaceuticals-announce-commercial-availability-of
https://www.nasdaq.com/press-release/ani-pharmaceuticals-completes-acquisition-of-novitium-pharma-significantly-enhancing
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-present-at-the-piper-sandler-33rd-annual-healthcare-conference
https://www.nasdaq.com/press-release/ani-pharmaceuticals-receives-clearance-from-u.s.-federal-trade-commission-for-the
https://www.nasdaq.com/press-release/ani-pharmaceuticals-inc.-announces-closing-of-%2475-million-public-offering-of-common
https://www.nasdaq.com/press-release/ani-pharmaceuticals-inc.-announces-pricing-of-%2475-million-public-offering-of-common
https://www.nasdaq.com/press-release/ani-pharmaceuticals-inc.-announces-proposed-public-offering-of-common-stock-2021-11
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-third-quarter-2021-results-2021-11-01
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-fda-approval-of-purified-cortrophintm-gel-for-multiple
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-discuss-third-quarter-2021-financial-results-on-november-1
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-present-at-cantor-virtual-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-launch-of-nebivolol-tablets-2021-09-17
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-fda-acceptance-of-purified-cortrophinr-gel-supplemental
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-second-quarter-2021-results-2021-08-06
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-discuss-second-quarter-2021-financial-results-on-august-6-2021
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-refiling-of-cortrophin-snda-with-fda-2021-07-06
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-present-at-the-raymond-james-human-health-innovation
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-details-of-2021-virtual-annual-meeting-of-stockholders
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-2021-2021
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-first-quarter-2021-results-2021-05-07
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-discuss-first-quarter-2021-financial-results-on-may-7-2021
https://www.nasdaq.com/press-release/ani-pharmaceuticals-expands-branded-products-portfolio-through-acquisition-of-sandoz
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-results-company
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-acquire-novitium-pharma-strengthening-rd-engine-and-expanding
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2021
https://www.nasdaq.com/press-release/ani-pharmaceuticals-strengthens-leadership-team-to-accelerate-future-growth-2021-02
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-discuss-fourth-quarter-and-full-year-2020-financial-results-on
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-launch-of-prazosin-hydrochloride-hcl-capsules-2021-02
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-approval-and-launch-of-aminocaproic-acid-tablets-2020
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-third-quarter-2020-results-2020-11-05
https://www.nasdaq.com/press-release/ani-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-2020-financial
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-09
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-second-quarter-2020-results-2020-08-06
https://www.nasdaq.com/press-release/ani-pharmaceuticals-appoints-experienced-pharmaceutical-executives-jeanne-thoma-and
https://www.nasdaq.com/press-release/ani-pharmaceuticals-names-nikhil-lalwani-as-president-and-chief-executive-officer
https://www.nasdaq.com/press-release/ani-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-2020
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-acquisition-of-fluconazole-tablets-2020-07-06
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-launch-of-mexiletine-hydrochloride-capsules-2020-06-30
https://www.nasdaq.com/press-release/ani-pharmaceuticals-provides-update-on-recent-regulatory-filing-2020-06-01
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-first-quarter-2020-results-and-appoints-interim-ceo-2020
https://www.nasdaq.com/press-release/ani-pharmaceuticals-schedules-conference-call-to-discuss-first-quarter-2020-financial
https://www.nasdaq.com/press-release/ani-receives-refusal-to-file-letter-from-fda-for-cortrophinr-gel-2020-04-29
https://www.nasdaq.com/press-release/ani-announces-upcoming-departure-of-ceo-2020-04-14
https://www.nasdaq.com/press-release/ani-announces-fda-acceptance-of-supplemental-filing-for-cortrophinr-gel-80-u-ml-2020
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-launch-of-omega-3-acid-ethyl-esters-capsules-usp-2020
https://www.nasdaq.com/press-release/ani-announces-launch-of-polyethylene-glycol-3350-17g-packet-2020-03-26
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-the-filing-of-a-prior-approval-supplement-for-purified
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-fda-approval-of-memantine-hydrochloride-extended
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-full-year-and-fourth-quarter-2019-results-provides-2020
https://www.nasdaq.com/press-release/ani-pharmaceuticals-schedules-conference-call-to-discuss-fourth-quarter-and-year-to
https://www.nasdaq.com/press-release/ani-announces-launch-of-sulfamethoxazole-and-trimethoprim-oral-suspension-usp-200-mg
https://www.nasdaq.com/press-release/ani-announces-launch-of-tolterodine-extended-release-capsules-2020-01-24
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-fda-approval-of-potassium-citrate-extended-release
https://www.nasdaq.com/press-release/ani-announces-launch-of-paliperidone-extended-release-tablets-2020-01-15
https://www.nasdaq.com/press-release/ani-announces-launch-of-paliperidone-extended-release-tablets-2020-01-14
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-acquisition-of-commercial-and-pipeline-generic-products
https://www.nasdaq.com/press-release/ani-pharmaceuticals-to-present-at-evercore-isi-2nd-annual-healthconx-conference-2019
https://www.nasdaq.com/press-release/ani-pharmaceuticals-reports-third-quarter-results-2019-11-06
https://www.nasdaq.com/press-release/ani-announces-plans-to-launch-bretylium-tosylate-injection-usp-500mg-10ml-50mg-ml-for
https://www.nasdaq.com/press-release/ani-pharmaceuticals-schedules-conference-call-to-discuss-third-quarter-and-year-to
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-the-launch-of-ani-global-source-its-contract
https://www.nasdaq.com/press-release/ani-announces-positive-clinical-results-from-cortrophinr-gel-cortisol-response-study
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-launch-of-aspirin-and-extended-release-dipyridamole
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-launch-of-vancomycin-hydrochloride-for-oral-solution
https://www.nasdaq.com/press-release/ani-pharmaceuticals-schedules-conference-call-to-discuss-second-quarter-and-year-to
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-launch-of-ranitidine-capsules-2019-06-25
https://www.nasdaq.com/press-release/ani-pharmaceuticals-announces-approval-of-vancomycin-hydrochloride-for-oral-solution
https://www.nasdaq.com/press-release/ani-pharmaceuticals-expands-generic-pipeline-with-acquisition-of-seven-development
https://www.nasdaq.com/press-release/ani-pharmaceuticals-present-raymond-james-life-sciences-and-medtech-conference-2019
https://www.nasdaq.com/press-release/ani-pharmaceuticals-schedules-conference-call-discuss-first-quarter-2019-financial
